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Abstract
To gain insight into potential regulatory mechanisms through which the effects of variants at four established type 2 diabetes
(T2D) susceptibility loci (CDKAL1, CDKN2A-B, IGF2BP2 and KCNQ1) are mediated, we undertook transancestral fine-mapping in
22 086 cases and 42 539 controls of East Asian, European, South Asian, African American and Mexican American descent.
Through high-density imputation and conditional analyses, we identified seven distinct association signals at these four loci,
each with allelic effects on T2D susceptibility that were homogenous across ancestry groups. By leveraging differences in the
structure of linkage disequilibrium between diverse populations, and increased sample size, we localised the variants most
likely to drive each distinct association signal. We demonstrated that integration of these genetic fine-mapping data with
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genomic annotation can highlight potential causal regulatory elements in T2D-relevant tissues. These analyses provide insight
into the mechanisms through which T2D association signals are mediated, and suggest future routes to understanding the
biology of specific disease susceptibility loci.
Introduction
Genome-wide association studies (GWAS) of type 2 diabetes
(T2D) have been extremely successful in identifying loci contrib-
uting genetic effects to disease susceptibility inmultiple ancestry
groups (1–5). These loci are typically characterized by common
variant association signals, defined by a lead single-nucleotide
polymorphism (SNP) with minor allele frequency (MAF) of at
least 5%, in the ancestry group inwhich itwas discovered. The as-
sociation signals oftenmap to large genomic intervals because of
extensive linkage disequilibrium (LD) between common variants
within populations from the same ancestry group, making local-
ization and identification of causal alleles at T2D susceptibility
loci extremely challenging. Consequently, there has been limited
progress in defining the molecular mechanisms through which
the effects of GWAS loci on disease are mediated.
There is increasing evidence, however, that T2D association
signals discovered in one ancestry group are transferrable across
diverse populations (6–9). For the majority of established T2D
susceptibility loci, common variant association signals are
shared across ancestries. Furthermore, there is limited evidence
across populations of heterogeneity in the allelic effects of lead
SNPs identified through transancestral meta-analysis (10). This
observation is consistent with a model in which the underlying
causal variants are shared across ancestry groups, and thus
arose prior to human population migration out of Africa. Under
this assertion, we expect to enhance the fine-mapping resolution
of causal alleles by combining GWAS across ancestry groups be-
cause of the increased sample size and as a result of differences
in the structure of LD between diverse populations (11–13).
To harness the power of transancestral fine-mapping for lo-
calizing potential causal variants for T2D susceptibility, we
have undertaken meta-analysis of GWAS in 22 086 cases and
42 539 controls from five ancestry groups: East Asian, European,
South Asian, African American and Mexican American (Supple-
mentary Material, Table S1). We focussed on four loci, mapping
to/near CDKAL1, CDKN2A-B, IGF2BP2 and KCNQ1, because they
harbour the strongest signals of association across diverse ances-
tries, with no evidence of heterogeneity in allelic effects between
populations (10). Previous ancestry-specific meta-analyses have
reported lead SNPs attaining genome-wide significance (P < 5 ×
10−8) at all four loci in European and East Asian descent popula-
tions (3,4), and at KCNQ1, also in African Americans (5). All four of
the loci have a primary physiological impact on T2D susceptibil-
ity via β-cell dysfunction (4), and thusmight be expected, a priori,
to share similar mechanisms through which the GWAS signals
are mediated.
Previous transancestral GWASmeta-analyses for T2D suscep-
tibility (10) have been limited by imputation up to the relatively
sparse reference panels from the International HapMap Consor-
tium (14), which provides limited coverage of variation with MAF
<5% across diverse populations. To improve fine-mapping reso-
lution, we have undertaken imputation of each study up to the
‘all ancestries’ reference panel from the 1000 Genomes Project
Consortium (15) (Phase 1 integrated release, March 2012) across
the four loci. With these data, we aimed to: (i) statistically delin-
eate distinct association signals arising frommultiple causal var-
iants in each locus through conditional analyses; (ii) re-evaluate
the evidence for heterogeneity in allelic effects between ancestry
groups for each distinct association signal; (iii) construct credible
sets of variants that are most likely to drive each distinct associ-
ation signal and thus most likely to incorporate causal alleles;
and (iv) interrogate credible set variants for predicted functional
annotation and regulatory sites in relevant tissues (primarily
pancreatic islet β-cells) to provide insight into the potential cau-
sal mechanisms through which the effects of each distinct asso-
ciation signal on T2D susceptibility are mediated.
Results
Study overview
We considered a total of 18 studies, genotyped with a range of
GWAS arrays, in 22 086 T2D cases and 42 539 controls (Supple-
mentary Material, Table S1): seven of East Asian ancestry (9867
cases and 12 870 controls), five of European ancestry (4555 cases
and 12 932 controls), four of South Asian ancestry (6196 cases and
13 775 controls), one of African American ancestry (631 cases and
2526 controls) and one of Mexican American ancestry (837 cases
and 436 controls). At each of the four loci, the GWAS scaffold in
each study was imputed up to the ‘all ancestries’ Phase 1 inte-
grated reference panel (March 2012 release) from the 1000 Gen-
omes Project Consortium (15) using IMPUTEv2 (16) or minimac
(17). We excluded variants with MAF <1% from each study, after
imputation, because our focus was on common and low-fre-
quency association signals that are shared across diverse popula-
tions, and thus amenable to transancestral fine-mapping to
improve localization of causal variants. We then retained ‘well-
imputed’ variants, defined as attaining widely used thresholds
(18) of IMPUTEv2 info ≥0.4 or minimac r2 ≥ 0.3, for downstream
association analyses.
We began, in each study, by testing for association of T2Dwith
each variant (MAF ≥1% and passing imputation quality control)
across the four loci (Materials and Methods, Supplementary
Material, Table S2). Variants passing quality control in <80% of
the total sample size (i.e. in <51 700 individuals) were excluded
from the transancestral meta-analysis. Our primary analysis
combined association summary statistics across studies using
MANTRA (19). This Bayesian method has been designed for
transancestral meta-analysis and fine-mapping by allowing for
heterogeneity in allelic odds ratios (ORs) between studies. Such
heterogeneity can arise as a result of differential patterns of LD
with a shared causal variant between diverse populations from
distinct ancestry groups. However MANTRA can also allow for
heterogeneity in allelic ORs arising from genuine effect size dif-
ferences between ancestry groups, including the possibility of
interaction with environmental risk factors that differ in expos-
ure between diverse populations, or variable phenotype defin-
ition or ascertainment strategies across studies.
MANTRA incorporates a prior model of relatedness between
studies to account for heterogeneity in allelic ORs, and has
been demonstrated, by simulation, to improve detection and
localization of causal variants compared with either a fixed- or
random-effects transancestral meta-analysis (19,20). Here, the
relatedness between studies has been developed by applying
hierarchical clustering to the observed pair-wise differences in
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mean allele frequency across variants at the four loci, and high-
lighted three distinct ancestral clades (Supplementary Material,
Fig. S1): (i) a single African American study (AfAm); (ii) a cluster
of studies of East Asian ancestry (EAsia) and (iii) a cluster of stud-
ies of European, Mexican American and South Asian ancestry
(Eur-MexAm-SAsia). The evidence in favour of association from
MANTRA is measured by means of a Bayes’ factor (BF). For com-
pleteness, we also combined association summary statistics
across studies through traditional fixed-effects meta-analysis,
which makes the limiting assumption of no heterogeneity in
allelic ORs between studies (Materials and Methods).
Identification of distinct association signals
There is increasing evidence ofmultiple ‘distinct’ association sig-
nals at established T2D susceptibility loci, each arising as a result
of different causal variants acting independently or, in cis, on
the same haplotype (4). The first stage in comprehensive fine-
mapping of GWAS loci is thus to disentangle, statistically, these
distinct association signals, and to localize the causal variants
for each, in turn, on the basis of conditional analyses. In this
framework, each distinct association signal can be represented
by an ‘index variant’, here required to attain genome-wide sig-
nificant evidence of association (MANTRA log10BF ≥6 and fixed-
effects P < 5 × 10−8) in conditional transancestral meta-analysis
(Materials and Methods). Across the four loci, we identified a
total of seven distinct signals of association, three mapping to
KCNQ1, two to CDKN2A-B and one each at IGF2BP2 and CDKAL1
(Table 1).
The association of variants mapping to the KCNQ1 locus with
T2D susceptibilitywas initially established in GWAS of East Asian
ancestry, andwas localized to a <50 kb intronic region of the gene
(21,22). Association of variants in this interval have been widely
replicated, at genome-wide significance, across GWAS frommul-
tiple populations (3,4,5,10). However, the lead SNPs from East
Asian and European ancestry meta-analyses are in only weak
LD with each other (rs2237896 and rs163184, respectively; CEU
r2 = 0.027, CHB + JPT r2 = 0.395). Meta-analyses of European ances-
try GWAS (4,23) have also identified an additional association sig-
nal at this locus, ∼150 kb upstream of the recombination interval
described above, and mapping to the KCNQ1-OT1 transcript that
controls regional imprinting (24). Through exact conditioning,
our transancestral meta-analysis has formally demonstrated
that the association at this locus can be delineated by three
distinct signals (Supplementary Material, Fig. S2), two localized
to the <50 kb KCNQ1 intronic recombination interval (rs2237897,
MANTRA log10BF = 9.79, P = 7.7 × 10
−12; rs233448, MANTRA
log10BF = 9.65, P = 9.5 × 10
−12) and one mapping to KCNQ1-OT1
(rs231353, MANTRA log10BF = 9.29, P = 1.7 × 10
−11). After account-
ing for these three index variants in conditional analyses, no re-
sidual association signal attains genome-wide significance
(maximum MANTRA log10BF = 3.38, P = 2.1 × 10
−5, rs223448).
At the CDKN2A-B locus, association of T2D susceptibility with
variants localized to a 12 kb intergenic recombination interval
was first reported in GWAS of European descent (25), and then
widely replicated across ancestry groups (3,4,5,10). Haplotype
analyses have revealed that the association signal can best be
explained by two partially correlated SNPs (rs10811661 and
rs10757282, CEU r2 = 0.360) in the recombination interval, acting
together, in cis, to impact disease risk (25–27). European ancestry
GWAS have also previously hinted at a distinct association signal
at this locus, mapping to the non-coding CDKN2B-AS1 (ANRIL)
transcript (4). Through exact conditioning, our transancestral
meta-analysis has demonstrated that the association at this
locus can be delineated by two distinct signals (Supplementary
Material, Fig. S3), both of which map to the 12 kb intergenic re-
combination interval described above (rs10965246, MANTRA
log10BF = 37.45, P = 8.4 × 10
−40; rs10757282, MANTRA log10BF =
10.31, P = 2.0 × 10−12). Furthermore, our results highlight that
these two index variants are sufficient to fully explain the
association across the locus, including that previously localized
to CDKN2B-AS1 (maximum MANTRA log10BF = 1.88, P = 0.21,
rs10811649).
Evaluation of heterogeneity in association signals
between ancestry groups
We next sought to evaluate the evidence for heterogeneity in al-
lelic effects between studies for the index variants for the seven
distinct association signals across the four loci on the basis of the
transancestral meta-analysis (Materials and Methods). We ob-
served no substantial differences in allelic OR, within or between
ancestry groups, for any association signal (assessed byMANTRA
log10BF of heterogeneity or Cochran’s Q statistic from the fixed-
effects meta-analysis). Any apparent differences in the magni-
tude of an association signal between ancestral clades, as mea-
sured by means of the log10BF or P-value, can be explained by
differences in the allele frequency of the index variant between
the diverse populations contributing to the meta-analysis (Sup-
plementary Material, Table S3). For example, the index variant
rs2237897, mapping to the KCNQ1 locus, demonstrates a stronger
signal of association after conditional analysis in the EAsia clade
(MANTRA log10BF = 5.55, fixed-effects P = 2.0 × 10
−7) than the Eur-
MexAm-SAsia clade (MANTRA log10BF = 4.04, fixed-effects P = 4.4
× 10−6), despite much smaller total sample size. However, the
minor allele is at much lower frequency in European, Mexican
Table 1. Summary statistics from the conditional transancestral meta-analysis (22 086 cases and 42 539 controls) for distinct T2D association
signals at each locus
Locus Index SNP Chr Position
(b37)
Alleles Mean (range) r2
or info
MANTRA Fixed-effects meta-analysis
Risk Other Log10BF Log10BF
heterogeneity
OR (95% CI) P-value Cochran’s Q
P-value
IGF2BP2 rs11705729 3 185 507 299 T C 0.96 (0.74–1.00) 19.35 −0.05 1.14 (1.11–1.17) 1.3 × 10−21 0.49
CDKAL1 rs9368222 6 20 686 996 A C 0.97 (0.74–1.00) 28.84 0.99 1.17 (1.14–1.21) 4.1 × 10−30 0.0058
CDKN2A-B rs10965246 9 22 132 698 T C 0.94 (0.79–1.00) 37.45 −0.03 1.31 (1.26–1.36) 8.4 × 10−40 0.0029
rs10757282 9 22 133 984 C T 0.92 (0.32–1.00) 10.31 0.01 1.12 (1.09–1.16) 2.0 × 10−12 0.17
KCNQ1 rs231353 11 2 709 019 G A 0.93 (0.68–0.99) 9.29 −0.13 1.11 (1.07–1.14) 1.7 × 10−11 0.79
rs233448 11 2 840 424 C T 0.94 (0.84–1.00) 9.65 0.14 1.12 (1.09–1.16) 9.5 × 10−12 0.18
rs2237897 11 2 858 546 C T 0.75 (0.35–0.97) 9.79 0.17 1.19 (1.14–1.26) 7.7 × 10−12 0.35
Chr, chromosome; OR, odds ratio; CI, confidence interval.
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American and South Asian ancestry populations (MAF = 0.05)
than in those of East Asian descent (MAF = 0.35), resulting in re-
duced power to detect association for the same allelic effect size.
Localization of variants driving T2D association signals
Wenext constructed ‘credible sets’ of SNPs (27) that aremost like-
ly to drive each of the seven distinct signals at the four loci on the
basis of their posterior probability of driving the association (πC)
from the MANTRA transancestral meta-analysis (Materials and
Methods, Table 2, Supplementary Material, Table S4). Assuming
that the variant driving the association signal has been imputed
from the 1000G reference panel, the probability that it will be con-
tained in the 99% credible set is 0.99. Smaller credible sets, in
terms of the number of SNPs they contain, or the genomic inter-
val that they cover, thus correspond to fine-mapping at higher
resolution. To assess the improvements in the resolution of
fine-mapping offered by transancestral meta-analysis, we com-
pared the properties of the 99% credible set for each of the
seven distinct association signals obtained from: (i) studies in
the EAsia clade only; (ii) studies in the Eur-MexAm-SAsia clade
only and (iii) studies from all populations, combining the two
clades with the single African American study. Note that
we have not reported summary statistics for the 99% credible
sets for theAfricanAmerican studyalone because the small sam-
ple size makes comparison of fine-mapping intervals with the
EAsia and Eur-MexAm-SAsia clades meaningless.
For each of the seven distinct association signals, fine-map-
ping resolution was improved after transancestral meta-analysis
when compared with either ancestral clade, in terms of the
number of SNPs reported in the credible set and/or the genomic
interval that they cover (Table 2). These improvements in reso-
lution could occur as a result of increased sample size, or because
of differences in the structure of LD between diverse populations,
but distinguishing between these possibilities is not straightfor-
ward. One approach is to quantify the extent of LD variation at a
locus between pairs of populations by means of the varLD statis-
tic (28). Using CEU, YRI and CHB + JPT reference haplotypes from
the International HapMap Consortium (14) as representative of
populations of European, African and East Asian ancestry,
respectively, the CDKAL1 locus has the greatest extent of LD vari-
ation among those investigated here, and thus would be ex-
pected to be most amenable to transancestral fine-mapping
(28). At this locus, the 99% credible set for the association signal
after transancestral meta-analysis included just five SNPs map-
ping to 12.3 kb, compared with 15 SNPs mapping to 34.4 kb
in the EAsia clade, and eight SNPs mapping to 40.4 kb in the
Eur-MexAm-SAsia clade (Fig. 1). The transancestral credible set
corresponds to the overlap of SNPs from the two ancestral clades,
and represents those that are in strong LD with the index variant
(rs9368222) in East Asian and European descent populations. In
contrast, the extent of variation in LD between CEU, YRI and CHB
+ JPT reference haplotypes from Phase II HapMap is lower at the
IGF2BP2 locus (28), where the improvement in the resolution of
fine-mapping after transancestral meta-analysis is less apparent
(Table 2). Variants in the 99% credible set for this association sig-
nal after transancestral meta-analysis are in strong LD with the
lead SNP in both East Asian and European descent populations
(CEU and CHB + JPT r2 > 0.7), so there is less gain for fine-mapping
over the EAsia and Eur-MexAm-SAsia clades.
After transancestral meta-analysis, themost precise localiza-
tion was observed for two of the association signals at the KCNQ1
locus, indexed by rs2237897 (3 SNPsmapping to 197 bp of the nar-
row intronic recombination interval) and rs231353 (3 SNPs map-
ping to 17.5 kb of KCNQ1-OT1). The 99% credible sets for both
association signals at the CDKN2A-B locus include a total of 12
non-overlapping SNPs mapping to the same <5 kb interval. We
interrogated the 99% credible sets for all seven distinct associ-
ation signals at the four loci for functional annotation. Despite
the high-resolution of fine-mapping for all but the IGF2BP2
association signal, the credible sets do not include any coding
variants. These data are thus consistent with previous genome-
wide reports that association signals for complex human traits
at GWAS loci are most likely to bemediated through gene regula-
tion (29,30).
Regulatory mechanisms through which credible set
variants influence T2D susceptibility
Recent reports have demonstrated a relationship between T2D-
associated variants, genome-wide, and transcriptional enhancer
activity, particularly in human pancreatic islets, liver cells, adi-
pose tissue and muscle (29–32). However, the precise biological
processes bywhich these variants impact on disease susceptibil-
ity at most GWAS loci remain obscure. Given the primary physio-
logical impact on T2D susceptibility of the four loci considered
here via β-cell dysfunction (4), we explored potential mechan-
isms through which the effects of the seven distinct association
signals are mediated by overlapping 99% credible set variants
with regions of predicted regulatory function in humanpancreat-
ic islets (32) (Materials and Methods). We observed that credible
set variants for four association signals (three at KCNQ1 and
one at CDKAL1) map to predicted tissue-specific enhancers in
human pancreatic islets, suggesting that they may play a role
in gene regulation (Fig. 2, Supplementary Material, Figs. S4–S6).
These variants included: rs231362 and rs231361 (at the KCNQ1
association signal indexed by rs231353, total πC = 0.359);
rs234866 (at the KCNQ1 association signal indexed by rs233448,
Table 2. Properties of the 99% credible sets of SNPs underlying each distinct association signal on the basis of meta-analyses of: (i) GWAS in the
EAsia clade only; (ii) GWAS in the Eur-MexAm-SAsia clade only and (iii) GWAS from all ancestry groups
Locus Index SNP EAsia meta-analysis Eur-MexAm-SAsia
meta-analysis
Transancestral meta-analysis
SNPs Distance (bp) SNPs Distance (bp) SNPs Distance (bp) Interval (b37)
IGF2BP2 rs11705729 51 52 598 40 39 163 36 31 027 185 503 456–185 534 482
CDKAL1 rs9368222 15 32 429 8 40 463 5 12 330 20 675 792–20 688 121
CDKN2A-B rs10965246 7 1556 7 2178 5 1371 22 132 698–22 134 068
rs10757282 26 50 986 7 5861 7 4435 22 133 251–22 137 685
KCNQ1 rs231353 289 462 551 6 38 477 3 17 549 2 691 471–2 709 019
rs233448 24 26 115 11 21 685 11 20 273 2 837 625–2 857 897
rs2237897 9 18 886 53 474 488 3 197 2 858 440–2 858 636
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πC = 0.048); rs2237897, rs2237896 and rs74046911 (the entire cred-
ible set at the KCNQ1 association signal indexed by rs2237897,
total πC = 0.990); and rs9348441 (at the lone CDKAL1 association
signal indexed by rs9368222, πC = 0.120).
To test a potential regulatory role of these variants, we
first scanned the enhancer region for potential transcription fac-
tor binding sequences (Materials and Methods). We determined
that rs231362, at the KCNQ1 association signal indexed by
rs231353, disrupts a bHLH-likemotif.Within the large super-fam-
ily of bHLH transcription factors, the best aligned scorewas found
for the recognition site of BHLHE40. However, we cannot exclude
the possibility of in vivo binding of other proteins from the same
family at this site. Electrophoretic mobility shift assay (EMSA),
performed using nuclear extracts obtained from the insulinoma
Figure 1. Fine-mapping of the association signal at the CDKAL1 locus on the basis of transancestralmeta-analysis of GWAS from all ancestry groups (top) and GWAS in the
EAsia and Eur-MexAm-SAsia ancestral clades only (bottom). Each point represents a SNP passing quality control in the transancestral meta-analysis, plotted with their
log10BF as a function of genomic position (NCBI Build 37). In each plot, the index SNP is represented by the purple symbol. The colour coding of all other SNPs indicates LD
with the index SNP (estimated from 1000Genomes Project reference haplotypes by EUR r2 for the transancestralmeta-analysis and Eur-Mex-SAsia clade, and byASN r2 for
the EAsia clade): red r2≥ 0.8; gold 0.6≤ r2 < 0.8; green 0.4≤ r2 < 0.6; cyan 0.2 ≤ r2 < 0.4; blue r2 < 0.2; grey r2 unknown. The shape of the plotting symbol corresponds to the
annotation of the SNP: upward triangle for framestop or splice; downward triangle for non-synonymous; square for synonymous or UTR; and circle for intronic or non-
coding. Recombination rates are estimated from Phase II HapMap and gene annotations are taken from the UCSC genome browser. The genomic interval covered by the
99% credible set of variants for the association signal from the transancestral and ancestry-specific meta-analyses are highlighted by the red bar.
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mouse β cell line MIN6 (Materials and Methods), confirmed that
rs231362 alters the binding of a protein complex in vitro (Fig. 2).
We next created allele-specific luciferase reporter constructs of
the predicted regulatory region overlapped by this association
signal, and measured enhancer activity in MIN6 cells (Materials
and Methods). This experiment confirmed the enhancer po-
tential of the genomic site, and revealed higher activity of the
haplotype of T2D-risk alleles, in cis, at rs231362 and rs231361
(Fig. 2). At the remaining association signals, allele-specific episo-
mal reporter assays tested in mouse MIN6 cells failed to demon-
strate enhancer activity at overlapping sites (Supplementary
Material, Figs. S4–S6). Taken together, these observations high-
light rs231362 as a potential functional variant, and point to the
alteration of pancreatic islet genome regulation as a possible
mechanism through which the association signal indexed by
rs231353 at the KCNQ1 locus is mediated.
Discussion
We have undertaken comprehensive transancestral fine-map-
ping of four established T2D susceptibility loci to localize poten-
tial causal variants for association signals in 22 086 cases and
42 539 controls fromdiverse populations. Our study has extended
previous transancestral T2D GWAS meta-analyses (10) through
1000G imputation and conditional analyses to improve fine-map-
ping resolution of distinct association signals in these loci. We
have confirmed previous reports of multiple distinct association
signals mapping to/near KCNQ1 and CDKN2A-B, which may re-
flect multiple causal variants acting in isolation or through
their joint effects, in cis, on the same haplotype. However, for
the first time, we have demonstrated that these distinct associ-
ation signals are shared across ancestry groups, with no evidence
of heterogeneity in allelic effects on T2D risk between popula-
tions for index SNPs, despite substantial variability in allele
frequencies.
The utility of transancestral fine-mapping relies on the
assumption that causal variants are shared across diverse popu-
lations. The lack of heterogeneity in allelic effects on T2D suscep-
tibility between populations for distinct association signals at the
four loci considered in this study is consistent with this assump-
tion. Previous evidence of the transferability of T2D association
signals across diverse populations (6–10) suggests that many es-
tablished common variant loci for the disease will also be amen-
able to transancestral fine-mapping. Future discovery efforts,
Figure 2.Allele-specific enhancer function at the KCNQ1 locus. (A) At theKCNQ1 association signal indexed by rs231353 (mapping to KCNQ1-OT1), 99% credible set variants
rs231362 and rs231361 overlap a human pancreatic islet predicted enhancer characterized by an enrichment of the active histone modification H3K27ac.
(B) Electrophoretic mobility shift assay, performed with MIN6 β-cells nuclear extracts, indicates allele-specific protein complex binding to the rs231362 variant. Allele
G of the variant rs231362 allows the binding of a protein complex which does not disappear after pre-incubation with an excess of rs231362-A unlabelled
oligonucleotide probe (competitor). (C) Luciferase assay shows reduced enhancer activity for haplotypes bearing the allele A compared with allele G of rs231362 in
MIN6 β-cells. The data are presented as mean ± standard deviation. Three independent experiments were performed in triplicate, and P-values were calculated by a
two-sided Student’s t-test. (D) Allele frequencies for credible set variants rs231362 and rs231361.
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with imputation up to larger, higher-density reference panels
with improved coverage across the MAF spectrum, would be ex-
pected to identify lower frequency association signals that are
more likely to be ancestry- or population-specific, and thus un-
likely to benefit from fine-mapping across diverse populations.
The resolution of fine-mapping (assessed by credible set
size) will depend, crucially, on the extent of differences in the
structure of LD between populations contributing to the transan-
cestralmeta-analysis (12).Weobserved themost precise localiza-
tion of causal variants for the T2D association signal mapping
near CDKAL1, which has the greatest difference in LD structure
between populations of European, East Asian and African ances-
try among those loci considered in our study (28). However, even
at the IGF2BP2 locus, where differences in LD between popula-
tions are less well defined, increased sample size in the transan-
cestral meta-analysis offered improved resolution over ancestry-
specificfine-mapping bymagnifying even small deviations in the
correlation of SNPs with the causal variant. We would expect,
therefore, that transancestral fine-mapping would enable im-
proved localization of T2D association signals across common
variant GWAS loci, with further enhancements obtained through
inclusion of additional African (American) descent populations,
where the extent of LD is minimized.
Our fine-mapping experiment provided no evidence that as-
sociation signals at the four susceptibility loci are driven by cod-
ing variants. Our data are thus consistent with previous genome-
wide reports that association signals for T2D susceptibility are
most likely to act via gene regulation (29,30). Here, using KCNQ1
as an exemplar, we have demonstrated how genetic fine-map-
ping and genomic annotation can be used to highlight potential
causal regulatory elements in disease-relevant tissues, thereby
providing insight into the mechanisms through which asso-
ciation signals are mediated, and routes to understand the
underlying biology of specific loci through directed functional ex-
perimentation. At this locus, our results highlight rs231362 as
having a gain-of-function effect on a pancreatic islet enhancer
element residing in intron 11 of the KCNQ1 gene and overlapping
the KCNQ1-OT1 non-coding transcript, a region previously de-
monstrated to harbour tissue-specific active enhancers in
mouse (33). While more experiments are needed to characterize
the protein complex binding this regulatory element, we deter-
mined that rs231362 alters a bHLH-like motif. Several bHLH tran-
scription factors are expressed in human pancreatic islets,
including key islet regulators such as NEUROD1 (34). The best
alignment score was found for the recognition site of the bHLH
transcription factor BHLHE40, a protein expressed in human pan-
creatic islets and shown to play a role during the specification of
pancreatic endocrine progenitor cells (35). However, the biologic-
al role of BHLHE40 in adult pancreatic islets remains unclear.
KCNQ1 encodes for the voltage-gated K+ channel Kv7.1 in
pancreatic β-cells. Over-expression of KCNQ1 in cultured MIN6
cells has been shown to decrease glucose induced insulin secre-
tion (36), and is thus in keeping with a gain-of-function regula-
tory mechanism in T2D susceptibility. Moreover, inhibition of
Kv7.1 in β-cells has been previously demonstrated to increase
exocytosis and secretion of insulin (37), and patients with loss-
of-function mutations in KCNQ1 exhibit increased insulin secre-
tion (38). Although further functional experimentation, beyond
the scope of this study, will be required to definitively establish
the gene target of the regulatory element overlapping variants
driving the KCNQ1-OT1 association signal, these data point to
KCNQ1 as a possible candidate.
At the remaining association signals, episomal reporter
assays performed in mouse MIN6 cells failed to demonstrate
enhancer activity at sites overlapping credible set variants.
While episomal assays cannot recapitulate the natural genomic
and chromatin context, approaches such as genome-editing
(39) could unmask a possible effect of these variants in their
cis-regulatory milieu and enable isolation of their impact on β-
cell gene expression and function.
In conclusion, we have demonstrated that transancestral
meta-analysis of GWAS from diverse populations can be used
to localize variants most likely to drive distinct association sig-
nals at T2D susceptibility loci. By integrating genetic fine-map-
ping with genomic information from diabetes-relevant tissues,
we have demonstrated the utility of this approach for elucidating
the mechanisms through which the effects of T2D association
signals at GWAS loci on disease susceptibility are mediated.
Our study and analytical protocols provide a prototype for future
transancestral fine-mapping of T2D susceptibility loci, genome-
wide. These efforts will be further enhanced by the release of
larger, ancestry-specific imputation reference panels that in-
corporate reference haplotypes from a wider spectrum of global
populations, and improved functional and regulatory genomic
annotation, thus promising an exciting opportunity to explicate
the, as yet, poorly understood pathophysiology of the disease.
Materials and Methods
Ethics statement
All human research was approved by the relevant institutional
review boards, and conducted according to the Declaration of
Helsinki. All participants provided written informed consent.
Study-level analysis
Sample and SNP quality control was undertaken in each study
(Supplementary Material, Table S1). In each of the four loci, the
clean GWAS scaffold was then imputed up to the 1000 Genomes
Project (Phase 1 integrated, all ancestries,March 2012 release) ref-
erence panel (15). Well-imputed variants, defined by IMPUTEv2
(16) info >0.4 or minimac (17) r2 > 0.3, were tested for association
with T2D in a logistic regression framework under an additive
model after adjustment for study-specific covariates (Supple-
mentary Material, Table S2), including principal components to
adjust for population structure. Under the assumption that the
underlying causal variants for association signals at these loci
are common and shared across ancestry groups, SNPs with
MAF <1% were excluded from downstream analyses.
Transancestral meta-analysis
Association summary statistics for each SNP were combined
across studies using two complementary approaches: (i) a
fixed-effects meta-analysis implemented in GWAMA (40) and
(ii) a Bayesian hybrid of fixed- and random-effectsmeta-analysis,
as implemented inMANTRA (19). Meta-analyses were performed
first across studies within each of the EAsia and Eur-MexAm-
SAsia ancestral clades (Supplementary Material, Fig. S1). Subse-
quently, meta-analyses were performed across all populations,
bringing together the AfAm study with those from the EAsia
and Eur-MexAm-SAsia ancestral clades. SNPs passing quality
control in <80%of the total sample size (N≥ 51 700)were excluded
from the transancestral meta-analysis.
The fixed-effects meta-analysis was performed by combining
allelic effect sizes across studies under an inverse-variance
weighting scheme (40). Genome-wide significance was defined
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by the standard threshold of P < 5 × 10−8. Heterogeneity in allelic
effects was assessed by means of Cochran’s Q statistic (41).
MANTRAwas developed specifically for the purposes of trans-
ancestral fine-mapping, and allows for heterogeneity in allelic ef-
fects between ancestry groups arising as a result of differences in
the structure of LDwith the causal variant between diverse popu-
lations. MANTRA assigns studies to clusters according to a Bayes-
ian partition model of relatedness between them, defined by
pair-wise genome-wide mean allele frequency differences (Sup-
plementary Material, Fig. S1). Genome-wide significance was de-
fined by a threshold of log10BF≥ 6, which has been demonstrated,
by simulation, to be approximately equivalent to P < 5 × 10−8
under a fixed-effectsmodel (19,20). MANTRA also provides an as-
sessment of the evidence of heterogeneity in allelic effects by
means of a BF, calculated by comparing amodel where all studies
are assigned to the same cluster, with one where the number of
clusters is unconstrained.
Identification of distinct association signals
We identified ‘index SNPs’ to represent distinct signals of associ-
ation attaining genome-wide significance (MANTRA log10BF ≥ 6
and P < 5 × 10−8) at each locus through a series of conditional ana-
lyses, described below. Conditional analyses were performed
in each study, testing for T2D association with well-imputed var-
iants in a logistic regression framework under an additive model
after adjustment for study-specific covariates (Supplementary
Material, Table S2), and inclusion of genotypes at other index var-
iants at the locus as additional covariates. Association summary
statistics for each SNP were then combined across studies by
means of a fixed-effects meta-analysis and MANTRA.
At the IGF2BP2 locus, we included genotypes at the lead SNP
(rs11705729) from the transancestral meta-analysis as an add-
itional covariate in the logistic regressionmodel, and no variants
attained at the locus genome-wide significance after condition-
ing. The strongest residual association signal in conditional ana-
lysis was achieved by rs1540390 (log10BF = 0.98, P = 0.012). We
concluded that there is one common variant association signal
mapping to the IGF2BP2 locus, indexed by rs11705729. Subse-
quent fine-mapping analyses were undertaken on the basis of
the unconditional transancestral meta-analysis at this locus.
At the CDKAL1 locus, we included genotypes at the lead SNP
(rs9368222) from the transancestral meta-analysis as an add-
itional covariate in the logistic regressionmodel, and no variants
at the locus attained genome-wide significance after condition-
ing. The strongest residual association signal was achieved by
rs2328574 (log10BF = 1.76, P = 0.027). We concluded that there is
one common variant association signal mapping to the CDKAL1
locus, indexed by rs936822. Subsequent fine-mapping analyses
were undertaken on the basis of the unconditional transancestral
meta-analysis at this locus.
At theCDKN2A-B locus,we first included genotypes at the lead
SNP (rs10965248) from the transancestral meta-analysis as an
additional covariate in the logistic regression model, and mul-
tiple variants at the locus attained genome-wide significance
(Supplementary Material, Fig. S3). The strongest residual associ-
ation signal was attained by rs10757282 (log10BF = 10.31, P = 2.0 ×
10−12). We next included genotypes at both rs10965248 and
rs10757282 as additional covariates in the logistic regression
model, and no variants at the locus attained genome-wide sig-
nificance after this second round of conditioning. The strongest
residual association signal was attained by rs10811649 (log10BF =
1.88, P = 0.21). We concluded that there are two distinct signals of
association mapping to the CDKN2A-B locus. Subsequent fine-
mapping analyses for distinct common variant association sig-
nals at this locus were thus based on: (i) conditional analysis
after adjustment for genotypes at rs10757282 as an additional
covariate (index variant rs10965246) and (ii) conditional analysis
after adjustment for genotypes at rs10965248 as an additional
covariate (index variant rs10757282).
At the KCNQ1 locus, visual inspection of the signal plot for
the transancestral meta-analysis revealed three SNPs that were
not in LD with each other in any ancestry group (r2 < 0.04), but
all attaining genome-wide significance: rs2237896, rs231353 and
rs234864 (Supplementary Material, Fig. S2). We thus included
genotypes at all three of these SNPs as additional covariates in
the logistic regression model, and no variants at the locus at-
tained genome-wide significance after conditioning. The stron-
gest residual association signal was achieved by rs233448
(log10BF = 3.38, P = 2.1 × 10
−5). We concluded that there are three
distinct common variant association signals mapping to the
KCNQ1 locus. Subsequent fine-mapping analyses for distinct as-
sociation signals at this locus were thus based on: (i) conditional
analysis after adjustment for genotypes at rs2237896 and
rs231353 as additional covariates (index variant rs233448);
(ii) conditional analysis after adjustment for genotypes at
rs2237896 and rs234864 (index variant rs231353) and (iii) condi-
tional analysis after adjustment for genotypes at rs231353 and
rs234864 (index variant rs2237897).
Credible set construction
We calculated the posterior probability that the jth variant, πCj, is
driving a distinct association signal by
πCj ¼
Λj
P
k Λk
;
where the summation is over all variants in the locus. In this ex-
pression, Λj is the MANTRA BF in favour of association from the
transancestral meta-analysis. In loci with multiple distinct sig-
nals of association (KCNQ1 and CDKN2A-B), results are presented
from conditional meta-analysis as described above. In loci with a
single association signal (IGF2BP2 and CDKAL1), results are pre-
sented from unconditional meta-analysis. A 99% credible set
(27) was then constructed by: (i) ranking all variants according
to their BF, Λj and (ii) including ranked variants until their cumu-
lative posterior probability exceeds 0.99.
For each association signal, credible sets were constructed on
the basis of the MANTRA BF in favour of association on the basis
of the following meta-analyses: (i) studies within the EAsia an-
cestral clade only; (ii) studies within the Eur-MexAm-SAsia an-
cestral clade only and (iii) all studies across ancestry groups.
Genomic annotation and functional study of credible
set variants
We overlapped annotations obtained from human pancreatic is-
lets (32) with variants in 99% credible sets using bedtools v2.17.0
(42). Scanning for motifs and motif annotation was performed
using HOMERv4.4 (43) with default settings. The selected
human islet predicted regulatory regions of length 1.5–1.9 kb
were PCR-amplified from human genomic DNA with Phusion
High-Fidelity DNA Polymerase (New England Biolabs), cloned
into pENTR/D-TOPO (Invitrogen, catalogue number K2400-20)
and shuttled into Gateway-adapted PGL4.23 (44) with Gateway
LR Clonase Enzyme Mix (Invitrogen, catalogue number 11791-
100). The plasmids were modified by site-directed mutagenesis
(QuickChange; Stratagene, Santa Clara, CA, USA) to produce the
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common and rare genotype of the associated variants and to re-
produce risk and protective haplotypes. Correctmutagenesiswas
confirmed by Sanger sequencing.
Mouse β-cells (MIN6) were co-transfected in triplicate wells
with pGL4.23-regulatory region and pRL using Lipofectamine
2000 (Invitrogen), and luciferase activity was measured after
48 h. Results were expressed as luciferase:renilla ratios in vectors
carrying putative regulatory regions, relative to the ratio in empty
PGL4.23 vector. Statistical significance was assessed using a two-
sided Student’s t-test across all experiments.
EMSAwas performedwithmouseMIN6 β-cell nuclear extracts
as previously described (45). The sequences of oligonucleotides
used in this assay to test both genotypes of the credible set vari-
ant rs231362 were:
rs231362: A 5′-GATCTTTGACCCTGCACATGACGGGCGAG-3́;
and
rs231362: G 5′-GATCTTTGACCCTGCACGTGACGGGCGAG-3́.
Supplementary Material
Supplementary Material is available at HMG online.
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